Saturday 17 October 2026
Export MDLN’s income statement to Excel — free account
Medline Inc.
MDLN Healthcare Medical Instruments & Supplies
Medline Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.4 billion, up 11.5% from fiscal 2024. In the quarter to June 2026, revenue grew 15.7% and free cash flow grew 3.42%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
35.96
0.61
−1.67%
Follow MDLN
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/S ratio |
+3 more quarters Free account |
0.00 | 0.00 | 1.27 | 1.14 |
P/FCF ratio |
0.00 | 10.06 | 15.96 | 14.67 | |
P/Operating CF |
0.00 | 19.51 | 88.46 | 47.27 | |
P/B ratio |
0.00 | 1.76 | 1.88 | 1.77 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.00 | 0.00 | 1.63 | 1.47 | |
EV/EBITDA |
0.00 | 0.00 | 4.58 | 4.35 | |
EV/Operating CF |
3.76 | 10.16 | 15.41 | 14.24 | |
EV/FCF |
4.66 | 13.20 | 20.48 | 18.97 | |
Quick Ratio |
— | 2.20 | 2.33 | 2.34 | |
Current Ratio |
— | 4.29 | 4.41 | 4.33 | |
Net Debt/EBITDA |
0.00 | 1.36 | 15.05 | 14.91 | |
Debt/Assets |
0.00% | 32.64% | 32.22% | 31.96% | |
Debt/Equity |
0.00 | 0.65 | 0.65 | 0.66 | |
Asset Turnover |
— | 0.00 | 0.76 | 1.51 | |
Operating CF/Net income |
0.59 | 9.58 | 3.19 | 11.92 | |
Capex/Depreciation |
(0.42) | (0.42) | (0.36) | (0.41) | |
Interest Coverage |
2.88 | — | 3.10 | 3.32 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
15.58% | 0.00% | 16.70% | 16.85% | |
Intangible Assets out of Total Assets |
0.00 | 0.57 | 0.56 | 0.55 | |
Share Based Compensation of Revenue |
0.22% | 0.00% | 0.31% | 0.38% | |
Graham Net Nets |
0.00 | (0.25) | (0.23) | (0.25) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow Yield |
0.00% | 9.94% | 6.27% | 6.82% | |
Revenue per Share |
0.00 | 9.61 | 8.98 | 8.97 | |
Operating CF per Share |
0.00 | 2.15 | 0.50 | 0.83 | |
Capex per Share |
0.00 | (0.55) | (0.12) | (0.13) | |
Free Cash Flow per Share |
0.00 | 1.60 | 0.39 | 0.70 | |
Cash per Share |
— | 2.39 | 2.73 | 3.12 | |
Shareholders Equity per Share |
0.00 | 23.81 | 23.63 | 22.26 | |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 23.81 | 23.63 | 22.26 | |
Free Cash Flow |
87.00 | 1,297.00 | 316.00 | 604.00 | |
Working Capital |
— | 8,189.00 | 8,644.00 | 9,032.00 | |
Capital Expenditures |
(110.00) | (447.00) | (96.00) | (111.00) | |
Net Current Asset Value |
0.00 | (8,519.00) | (8,485.00) | (8,531.00) | |
EV/EBIT |
0.00 | 0.00 | 4.97 | 4.73 | |
Capex to Sales |
0.02 | 0.06 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 3.87 | 3.66 | |
| Other line items | |||||
Average Assets |
— | 19,242.00 | 37,496.00 | 19,675.00 |
Columns are period end dates